Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Research and Innovation Action · Running

INFRAPLUS Enhancing and Evolving INFRAFRONTIER Disease Modelling Capacity to Enable Breakthrough Research

Coordinator
Infrafrontier Eric, Germany
Runs
1 June 2024 to 31 May 2027
Status
Running
EU funding
€4.0m
Total cost
€5.0m
Partners
20 organisations in 13 countries
Type
Research and Innovation Action
Grant agreement
101131669

What the project is doing

In the project's own words, from its summary on CORDIS.

In response to the HORIZON-INFRA-2023-DEV-01-03 call, INFRAPLUS aims to expand INFRAFRONTIER's capacity for human disease modelling, refine its service portfolio by reducing animal usage and developing alternative cellular models, and optimise the use of resources. INFRAPLUS seeks to achieve several objectives: Developing national node capacities and expertise for providing innovative in vivo, in vitro and preclinical services, developing novel model systems and services to meet the demands of existing and novel user communities, and reducing environmental impact.

To achieve these objectives, INFRAPLUS will focus on launching pilot services, refining new technologies, emphasising alternate cellular models, designing and implementing special training programmes and optimising resources for the entire consortium. The project includes a defined service development strategy supported by a strong IT and data management backbone and is built upon the needs of the scientific community.

Ultimately, INFRAPLUS will enhance and evolve INFRAFRONTIER's capacity for modelling human diseases and enable breakthrough research by providing researchers cutting-edge tools and services to respond to global biomedical challenges.

Who is involved

OrganisationCityCountryRole
Infrafrontier EricNeuherbergGermanyCoordinator
Veterinaermedizinische Universitaet WienWienAustriaParticipant
The Hospital for Sick ChildrenTorontoCanadaAssociatedpartner
Ustav Molekularni Genetiky Av Cr V.v.i.Praha 4CzechiaParticipant
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt GmbHNeuherbergGermanyParticipant
Biomedcode Ellas Anonimi Eteria Epistimonikis Kai Texnologikis Erevnas Kai Emborikis Ekmetallefsis Epharmogon IatrikisVariGreeceParticipant
Erevnitiko Kentro Vioiatrikon Epistimon Alexandros FlemingkVari-AthensGreeceParticipant
Agencia Estatal Consejo Superior De Investigaciones CientificasMadridSpainParticipant
Universitat Autonoma De BarcelonaCerdanyola Del VallesSpainParticipant
Finnadvance OyHelsinkiFinlandParticipant
Oulun YliopistoOuluFinlandParticipant
Centre Europeen De Recherche En Biologie Et En MedecineIllkirch CedexFranceParticipant
Centre National De La Recherche Scientifique CNRSParisFranceParticipant
Institut National De La Sante Et De La Recherche MedicaleParisFranceAssociatedpartner
Consiglio Nazionale Delle RicercheRomaItalyParticipant
Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek ZiekenhuisAmsterdamNetherlandsParticipant
Fundacao Calouste GulbenkianLisboaPortugalParticipant
Fundacao Gimm - Gulbenkian Institute for Molecular MedicineLisboaPortugalParticipant
Karolinska InstitutetStockholmSwedenParticipant
United Kingdom Research and InnovationSwindonUnited KingdomParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI